Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 412.5 GBX -1.43% Market Closed
Market Cap: 434.6m GBX
Have any thoughts about
Oxford BioMedica PLC?
Write Note

EV/EBIT
Enterprise Value to EBIT

-6.8
Current
-4.6
Median
3.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-6.8
=
Enterprise Value
458.5m GBX
/
EBIT
-67m GBP
All Countries
Close
Market Cap EV/EBIT
UK
Oxford BioMedica PLC
LSE:OXB
434.4m GBP -6.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -214 979.3
US
Abbvie Inc
NYSE:ABBV
300.2B USD 22.8
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.8B USD 28.1
US
Gilead Sciences Inc
NASDAQ:GILD
114.8B USD 10.1
US
Epizyme Inc
F:EPE
94.1B EUR -505.7
AU
CSL Ltd
ASX:CSL
137.3B AUD 25.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.3B USD 19.4
US
Seagen Inc
F:SGT
39.3B EUR -53.6
NL
argenx SE
XBRU:ARGX
34.1B EUR -75.9
EBIT Growth
UK
Oxford BioMedica PLC
LSE:OXB
Average EV/EBIT: 23.2
Negative Multiple: -6.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 979.3 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
25.7
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -75.9 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-11
2-Years Forward
EV/EBIT
-23.5
3-Years Forward
EV/EBIT
83.6

See Also

Discover More